{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T14:18:10Z","timestamp":1791987490955,"version":"4.4.0"},"reference-count":92,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T00:00:00Z","timestamp":1759449600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82422068"],"award-info":[{"award-number":["82422068"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004731","name":"Natural Science Foundation of Zhejiang Province","doi-asserted-by":"publisher","award":["LDG25H300001"],"award-info":[{"award-number":["LDG25H300001"]}],"id":[{"id":"10.13039\/501100004731","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004731","name":"Natural Science Foundation of Zhejiang Province","doi-asserted-by":"publisher","award":["LR24H300001"],"award-info":[{"award-number":["LR24H300001"]}],"id":[{"id":"10.13039\/501100004731","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmn.com","cell.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Trends in Pharmacological Sciences"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.tips.2025.09.004","type":"journal-article","created":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T12:14:24Z","timestamp":1761048864000},"page":"1091-1104","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"title":["Next-generation isoform-selective fibroblast growth factor receptor inhibitors"],"prefix":"10.1016","volume":"46","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0089-6559","authenticated-orcid":false,"given":"Lingfeng","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.tips.2025.09.004_bb0005","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1038\/s41573-024-01125-w","article-title":"FGF-based drug discovery: advances and challenges","volume":"24","author":"Chen","year":"2025","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.tips.2025.09.004_bb0010","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1038\/s41586-023-06155-9","article-title":"Structural basis for FGF hormone signalling","volume":"618","author":"Chen","year":"2023","journal-title":"Nature"},{"key":"10.1016\/j.tips.2025.09.004_bb0015","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1038\/nature25010","article-title":"Structures of \u03b2-klotho reveal a 'zip code'-like mechanism for endocrine FGF signalling","volume":"553","author":"Lee","year":"2018","journal-title":"Nature"},{"key":"10.1016\/j.tips.2025.09.004_bb0020","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1038\/nrc.2017.8","article-title":"Advances and challenges in targeting FGFR signalling in cancer","volume":"17","author":"Babina","year":"2017","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.tips.2025.09.004_bb0025","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.jtho.2018.09.014","article-title":"Detection of known and novel FGFR fusions in non-small cell lung cancer by comprehensive genomic profiling","volume":"14","author":"Qin","year":"2019","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.tips.2025.09.004_bb0030","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1634\/theoncologist.2013-0352","article-title":"New routes to targeted therapy of intrahepatic cholangiocarcinomas revealed by next-generation sequencing","volume":"19","author":"Ross","year":"2014","journal-title":"Oncologist"},{"key":"10.1016\/j.tips.2025.09.004_bb0035","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1158\/1078-0432.CCR-14-3212","article-title":"The FGFR landscape in cancer: analysis of 4,853 tumors by next-generation sequencing","volume":"22","author":"Helsten","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.tips.2025.09.004_bb0040","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.21037\/atm-20-5118","article-title":"A comprehensive pan-cancer study of fibroblast growth factor receptor aberrations in Chinese cancer patients","volume":"8","author":"Sun","year":"2020","journal-title":"Ann. Transl. Med."},{"key":"10.1016\/j.tips.2025.09.004_bb0045","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1186\/s13045-024-01558-1","article-title":"Targeting FGFR for cancer therapy","volume":"17","author":"Zhang","year":"2024","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.tips.2025.09.004_bb0050","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1038\/s41571-024-00869-z","article-title":"FGFR-targeted therapeutics: clinical activity, mechanisms of resistance and new directions","volume":"21","author":"Katoh","year":"2024","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.tips.2025.09.004_bb0055","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1038\/s41392-020-00222-7","article-title":"FGF\/FGFR signaling in health and disease","volume":"5","author":"Xie","year":"2020","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.tips.2025.09.004_bb0060","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1186\/s13046-021-02156-6","article-title":"Fibroblast growth factor receptor fusions in cancer: opportunities and challenges","volume":"40","author":"Chen","year":"2021","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.tips.2025.09.004_bb0065","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1056\/NEJMoa1817323","article-title":"Erdafitinib in locally advanced or metastatic urothelial carcinoma","volume":"381","author":"Loriot","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.tips.2025.09.004_bb0070","doi-asserted-by":"crossref","first-page":"24252","DOI":"10.18632\/oncotarget.8132","article-title":"Landscape of activating cancer mutations in FGFR kinases and their differential responses to inhibitors in clinical use","volume":"7","author":"Patani","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.tips.2025.09.004_bb0075","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.annonc.2023.10.003","article-title":"Erdafitinib versus pembrolizumab in pretreated patients with advanced or metastatic urothelial cancer with select FGFR alterations: cohort 2 of the randomized phase III THOR trial","volume":"35","author":"Siefker-Radtke","year":"2024","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.tips.2025.09.004_bb0080","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1158\/2159-8290.CD-19-0182","article-title":"TAS-120 overcomes resistance to ATP-competitive FGFR inhibitors in patients with FGFR2 fusion-positive intrahepatic cholangiocarcinoma","volume":"9","author":"Goyal","year":"2019","journal-title":"Cancer Discov."},{"key":"10.1016\/j.tips.2025.09.004_bb0085","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1056\/NEJMoa2411790","article-title":"Oral infigratinib therapy in children with achondroplasia","volume":"392","author":"Savarirayan","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.tips.2025.09.004_bb0090","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2500017","article-title":"Pemigatinib for myeloid\/lymphoid neoplasms with FGFR1 rearrangement","volume":"4","author":"Verstovsek","year":"2025","journal-title":"NEJM Evid."},{"key":"10.1016\/j.tips.2025.09.004_bb0095","article-title":"Pemigatinib: hot topics behind the first approval of a targeted therapy in cholangiocarcinoma","volume":"27","author":"Rizzo","year":"2021","journal-title":"Cancer Treat. Res. Commun."},{"key":"10.1016\/j.tips.2025.09.004_bb0100","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1080\/17474124.2021.1911646","article-title":"FGFR inhibitors in elderly patients with advanced biliary tract cancer: an unsolved issue","volume":"15","author":"Rizzo","year":"2021","journal-title":"Expert Rev. Gastroenterol. Hepatol."},{"key":"10.1016\/j.tips.2025.09.004_bb0105","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1200\/JCO.2017.75.5009","article-title":"Phase II study of BGJ398 in patients with FGFR-altered advanced cholangiocarcinoma","volume":"36","author":"Javle","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.tips.2025.09.004_bb0110","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2024.103488","article-title":"An open-label study of pemigatinib in cholangiocarcinoma: final results from FIGHT-202","volume":"9","author":"Vogel","year":"2024","journal-title":"ESMO Open"},{"key":"10.1016\/j.tips.2025.09.004_bb0115","doi-asserted-by":"crossref","first-page":"458","DOI":"10.3390\/medicina57050458","article-title":"Targeted therapies in advanced cholangiocarcinoma: a focus on FGFR inhibitors","volume":"57","author":"Rizzo","year":"2021","journal-title":"Medicina (Kaunas)"},{"key":"10.1016\/j.tips.2025.09.004_bb0120","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1080\/14737140.2023.2192930","article-title":"Pemigatinib for the treatment of myeloid\/lymphoid neoplasms with FGFR1 rearrangement","volume":"23","author":"Freyer","year":"2023","journal-title":"Expert. Rev. Anticancer. Ther."},{"key":"10.1016\/j.tips.2025.09.004_bb0125","doi-asserted-by":"crossref","first-page":"1961","DOI":"10.1056\/NEJMoa2308849","article-title":"Erdafitinib or chemotherapy in advanced or metastatic urothelial carcinoma","volume":"389","author":"Loriot","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.tips.2025.09.004_bb0130","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1158\/1535-7163.MCT-16-0589","article-title":"Discovery and pharmacological characterization of JNJ-42756493 (erdafitinib), a functionally selective small-molecule FGFR family inhibitor","volume":"16","author":"Perera","year":"2017","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.tips.2025.09.004_bb0135","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1182\/blood-2021-148103","article-title":"A phase 2 study of pemigatinib (FIGHT-203; INCB054828) in patients with myeloid\/lymphoid neoplasms (MLNs) with fibroblast growth factor receptor 1 (FGFR1) rearrangement (MLN FGFR1)","volume":"138","author":"Gotlib","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.tips.2025.09.004_bb0140","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1038\/s41591-024-02934-7","article-title":"Pemigatinib in previously treated solid tumors with activating FGFR1-FGFR3 alterations: phase 2 FIGHT-207 basket trial","volume":"30","author":"Rodon","year":"2024","journal-title":"Nat. Med."},{"key":"10.1016\/j.tips.2025.09.004_bb0145","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1016\/S2468-1253(21)00196-5","article-title":"Infigratinib (BGJ398) in previously treated patients with advanced or metastatic cholangiocarcinoma with FGFR2 fusions or rearrangements: mature results from a multicentre, open-label, single-arm, phase 2 study","volume":"6","author":"Javle","year":"2021","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"10.1016\/j.tips.2025.09.004_bb0150","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1016\/S1470-2045(23)00275-9","article-title":"Erdafitinib in patients with advanced solid tumours with FGFR alterations (RAGNAR): an international, single-arm, phase 2 study","volume":"24","author":"Pant","year":"2023","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.tips.2025.09.004_bb0155","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1056\/NEJMoa2206834","article-title":"Futibatinib for FGFR2-rearranged intrahepatic cholangiocarcinoma","volume":"388","author":"Goyal","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.tips.2025.09.004_bb0160","doi-asserted-by":"crossref","first-page":"2968","DOI":"10.3390\/cancers13122968","article-title":"FGFR inhibitors in oncology: insight on the management of toxicities in clinical practice","volume":"13","author":"Kommalapati","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.tips.2025.09.004_bb0165","article-title":"Clinical development and management of adverse events associated with FGFR inhibitors","volume":"4","author":"Subbiah","year":"2023","journal-title":"Cell Rep. Med."},{"key":"10.1016\/j.tips.2025.09.004_bb0170","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1146\/annurev-med-042921-024707","article-title":"FGFR2 inhibition in cholangiocarcinoma","volume":"74","author":"Vogel","year":"2023","journal-title":"Annu. Rev. Med."},{"key":"10.1016\/j.tips.2025.09.004_bb0175","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1158\/1078-0432.CCR-23-1317","article-title":"Landscape of clinical resistance mechanisms to FGFR inhibitors in FGFR2-altered cholangiocarcinoma","volume":"30","author":"Wu","year":"2024","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.tips.2025.09.004_bb0180","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2213090120","article-title":"Gatekeeper mutations activate FGF receptor tyrosine kinases by destabilizing the autoinhibited state","volume":"120","author":"Besch","year":"2023","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.tips.2025.09.004_bb0185","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1038\/s42004-022-00718-z","article-title":"Characterization of the cholangiocarcinoma drug pemigatinib against FGFR gatekeeper mutants","volume":"5","author":"Lin","year":"2022","journal-title":"Commun. Chem."},{"key":"10.1016\/j.tips.2025.09.004_bb0190","doi-asserted-by":"crossref","first-page":"2012","DOI":"10.1158\/2159-8290.CD-23-0475","article-title":"RLY-4008, the first highly selective FGFR2 inhibitor with activity across FGFR2 alterations and resistance mutations","volume":"13","author":"Subbiah","year":"2023","journal-title":"Cancer Discov."},{"key":"10.1016\/j.tips.2025.09.004_bb0195","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1158\/2159-8290.CD-16-1000","article-title":"Polyclonal secondary FGFR2 mutations drive acquired resistance to FGFR inhibition in patients with FGFR2 fusion-positive cholangiocarcinoma","volume":"7","author":"Goyal","year":"2017","journal-title":"Cancer Discov."},{"key":"10.1016\/j.tips.2025.09.004_bb0200","doi-asserted-by":"crossref","DOI":"10.1177\/1758835920953293","article-title":"FGFR inhibitors in cholangiocarcinoma: what's now and what's next?","volume":"12","author":"Saborowski","year":"2020","journal-title":"Ther. Adv. Med. Oncol."},{"key":"10.1016\/j.tips.2025.09.004_bb0205","doi-asserted-by":"crossref","first-page":"4586","DOI":"10.1158\/1078-0432.CCR-23-1283","article-title":"Clinical and genomic landscape of FGFR3-altered urothelial carcinoma and treatment outcomes with erdafitinib: a real-world experience","volume":"29","author":"Guercio","year":"2023","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.tips.2025.09.004_bb0210","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2317756121","article-title":"Discovery of lirafugratinib (RLY-4008), a highly selective irreversible small-molecule inhibitor of FGFR2","volume":"121","author":"Schonherr","year":"2024","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.tips.2025.09.004_bb0215","doi-asserted-by":"crossref","first-page":"1964","DOI":"10.1158\/2159-8290.CD-23-0728","article-title":"FGFR inhibition: understanding and overcoming resistance","volume":"13","author":"Tripathi","year":"2023","journal-title":"Cancer Discov."},{"key":"10.1016\/j.tips.2025.09.004_bb0220","doi-asserted-by":"crossref","first-page":"4009","DOI":"10.1200\/JCO.2023.41.16_suppl.4009","article-title":"Updated dose escalation results for ReFocus, a first-in-human study of highly selective FGFR2 inhibitor RLY-4008 in cholangiocarcinoma and other solid tumors","volume":"41","author":"Borad","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.tips.2025.09.004_bb0225","article-title":"Clinical activity of lirafugratinib (RLY-4008), a highly selective FGFR2 inhibitor, in patients with advanced FGFR2-altered solid tumors: the ReFocus study","volume":"22","author":"Schram","year":"2023"},{"key":"10.1016\/j.tips.2025.09.004_bb0230","doi-asserted-by":"crossref","first-page":"P141","DOI":"10.1158\/1535-7163.TARG-21-P141","article-title":"Preclinical characterization of LOX-24350, a highly potent and isoform-selective FGFR3 inhibitor","volume":"20","author":"Ballard","year":"2021","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.tips.2025.09.004_bb0235","doi-asserted-by":"crossref","DOI":"10.1158\/1538-7445.AM2023-CT119","article-title":"A first-in-human phase 1 study of LOXO-435, a potent, highly isoform-selective FGFR3 inhibitor in advanced solid tumors with FGFR3 alterations","volume":"83","author":"Iyer","year":"2023","journal-title":"Cancer Res."},{"key":"10.1016\/j.tips.2025.09.004_bb0240","doi-asserted-by":"crossref","first-page":"16737","DOI":"10.1021\/acs.jmedchem.4c01531","article-title":"Discovery of TYRA-300: first oral selective FGFR3 inhibitor for the treatment of urothelial cancers and achondroplasia","volume":"67","author":"Hudkins","year":"2024","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.tips.2025.09.004_bb0245","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1021\/acsmedchemlett.3c00003","article-title":"Discovery of orally bioavailable FGFR2\/FGFR3 dual inhibitors via structure-guided scaffold repurposing approach","volume":"14","author":"Nguyen","year":"2023","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.tips.2025.09.004_bb0250","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1021\/acsmedchemlett.5c00232","article-title":"Discovery of INCB126503 as a potent and selective FGFR2\/3 inhibitor","volume":"16","author":"Nguyen","year":"2025","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.tips.2025.09.004_bb0255","doi-asserted-by":"crossref","first-page":"3886","DOI":"10.1021\/acs.jmedchem.4c03205","article-title":"Discovery of pyrrolopyrazine carboxamide derivatives as potent and selective FGFR2\/3 inhibitors that overcome mutant resistance","volume":"68","author":"Wang","year":"2025","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.tips.2025.09.004_bb0260","doi-asserted-by":"crossref","first-page":"13887","DOI":"10.1021\/acs.jmedchem.5c00928","article-title":"Rational design and identification of ISM7594 as a tissue-agnostic FGFR2\/3 inhibitor","volume":"68","author":"Wang","year":"2025","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.tips.2025.09.004_bb0265","doi-asserted-by":"crossref","first-page":"15433","DOI":"10.1021\/acs.jmedchem.2c01366","article-title":"Discovery of potent and selective inhibitors of wild-type and gatekeeper mutant fibroblast growth factor receptor (FGFR) 2\/3","volume":"65","author":"Shvartsbart","year":"2022","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.tips.2025.09.004_bb0270","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/s13046-016-0478-9","article-title":"FGF19\/FGFR4 signaling contributes to the resistance of hepatocellular carcinoma to sorafenib","volume":"36","author":"Gao","year":"2017","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.tips.2025.09.004_bb0275","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1158\/2159-8290.CD-14-1029","article-title":"First selective small molecule inhibitor of FGFR4 for the treatment of hepatocellular carcinomas with an activated FGFR4 signaling pathway","volume":"5","author":"Hagel","year":"2015","journal-title":"Cancer Discov."},{"key":"10.1016\/j.tips.2025.09.004_bb0280","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1158\/2159-8290.CD-19-0555","article-title":"First-in-human phase I study of fisogatinib (BLU-554) validates aberrant FGF19 signaling as a driver event in hepatocellular carcinoma","volume":"9","author":"Kim","year":"2019","journal-title":"Cancer Discov."},{"key":"10.1016\/j.tips.2025.09.004_bb0285","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1007\/s10637-023-01335-w","article-title":"A phase Ib\/II study of BLU-554, a fibroblast growth factor receptor 4 inhibitor in combination with CS1001, an anti-PD-L1, in patients with locally advanced or metastatic hepatocellular carcinoma","volume":"41","author":"Zhou","year":"2023","journal-title":"Investig. New Drugs"},{"key":"10.1016\/j.tips.2025.09.004_bb0290","doi-asserted-by":"crossref","first-page":"1686","DOI":"10.1158\/2159-8290.CD-19-0367","article-title":"Acquired on-target clinical resistance validates FGFR4 as a driver of hepatocellular carcinoma","volume":"9","author":"Hatlen","year":"2019","journal-title":"Cancer Discov."},{"key":"10.1016\/j.tips.2025.09.004_bb0295","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/s13045-021-01040-2","article-title":"FGFR-TKI resistance in cancer: current status and perspectives","volume":"14","author":"Yue","year":"2021","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.tips.2025.09.004_bb0300","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1021\/cb500674s","article-title":"DFG-out mode of inhibition by an irreversible type-1 inhibitor capable of overcoming gate-keeper mutations in FGF receptors","volume":"10","author":"Huang","year":"2015","journal-title":"ACS Chem. Biol."},{"key":"10.1016\/j.tips.2025.09.004_bb0305","doi-asserted-by":"crossref","first-page":"12542","DOI":"10.1021\/acs.jmedchem.0c01019","article-title":"Discovery of roblitinib (FGF401) as a reversible-covalent inhibitor of the kinase activity of fibroblast growth factor receptor 4","volume":"63","author":"Fairhurst","year":"2020","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.tips.2025.09.004_bb0310","doi-asserted-by":"crossref","first-page":"5890","DOI":"10.1039\/C9CC02052G","article-title":"Characterization of FGF401 as a reversible covalent inhibitor of fibroblast growth factor receptor 4","volume":"55","author":"Zhou","year":"2019","journal-title":"Chem. Commun. (Camb.)"},{"key":"10.1016\/j.tips.2025.09.004_bb0315","doi-asserted-by":"crossref","first-page":"14276","DOI":"10.1021\/acs.jmedchem.2c01159","article-title":"Blocking non-enzymatic functions by PROTAC-mediated targeted protein degradation","volume":"65","author":"Sun","year":"2022","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.tips.2025.09.004_bb0320","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.cell.2019.11.031","article-title":"Proteolysis-targeting chimeras as therapeutics and tools for biological discovery","volume":"181","author":"Burslem","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.tips.2025.09.004_bb0325","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1038\/s41571-023-00736-3","article-title":"Protein degraders enter the clinic - a new approach to cancer therapy","volume":"20","author":"Chirnomas","year":"2023","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.tips.2025.09.004_bb0330","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1038\/s41573-021-00371-6","article-title":"PROTAC targeted protein degraders: the past is prologue","volume":"21","author":"Bekes","year":"2022","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.tips.2025.09.004_bb0335","doi-asserted-by":"crossref","first-page":"5740","DOI":"10.1039\/D2CS00200K","article-title":"Target and tissue selectivity of PROTAC degraders","volume":"51","author":"Guenette","year":"2022","journal-title":"Chem. Soc. Rev."},{"key":"10.1016\/j.tips.2025.09.004_bb0340","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmcl.2022.128982","article-title":"Development of selective FGFR1 degraders using a rapid synthesis of proteolysis targeting chimera (rapid-TAC) platform","volume":"75","author":"Guo","year":"2022","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.tips.2025.09.004_bb0345","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2024.116612","article-title":"Design, synthesis and antitumor activity of a novel FGFR2-selective degrader to overcome resistance of the FGFR2(V564F) gatekeeper mutation based on a pan-FGFR inhibitor","volume":"275","author":"Hu","year":"2024","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.tips.2025.09.004_bb0350","doi-asserted-by":"crossref","DOI":"10.1158\/1535-7163.MCT-23-0719","article-title":"A selective FGFR1\/2 PROTAC degrader with antitumor activity","author":"Kong","year":"2024","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.tips.2025.09.004_bb0355","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2024.108109","article-title":"Design, synthesis, and biological evaluation of novel FGFR1 PROTACs","volume":"155","author":"Wang","year":"2025","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.tips.2025.09.004_bb0360","doi-asserted-by":"crossref","first-page":"15905","DOI":"10.1002\/anie.202101328","article-title":"Discovery of a potent degrader for fibroblast growth factor receptor 1\/2","volume":"60","author":"Du","year":"2021","journal-title":"Angew. Chem. Int. Ed. Engl."},{"key":"10.1016\/j.tips.2025.09.004_bb0365","doi-asserted-by":"crossref","first-page":"7438","DOI":"10.1021\/acs.jmedchem.3c00150","article-title":"Discovery of a selective and orally bioavailable FGFR2 degrader for treating gastric cancer","volume":"66","author":"Ma","year":"2023","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.tips.2025.09.004_bb0370","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1021\/acsmedchemlett.0c00556","article-title":"Solution conformations shed light on PROTAC cell permeability","volume":"12","author":"Atilaw","year":"2021","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.tips.2025.09.004_bb0375","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1021\/acs.jcim.1c01036","article-title":"Impact of PROTAC linker plasticity on the solution conformations and dissociation of the ternary complex","volume":"62","author":"Weerakoon","year":"2022","journal-title":"J. Chem. Inf. Model."},{"key":"10.1016\/j.tips.2025.09.004_bb0380","doi-asserted-by":"crossref","first-page":"E7285","DOI":"10.1073\/pnas.1803662115","article-title":"Delineating the role of cooperativity in the design of potent PROTACs for BTK","volume":"115","author":"Zorba","year":"2018","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.tips.2025.09.004_bb0385","doi-asserted-by":"crossref","first-page":"5969","DOI":"10.1038\/s41467-022-33430-6","article-title":"A selective and orally bioavailable VHL-recruiting PROTAC achieves SMARCA2 degradation in vivo","volume":"13","author":"Kofink","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.tips.2025.09.004_bb0390","doi-asserted-by":"crossref","first-page":"13858","DOI":"10.1021\/acs.jmedchem.5c00731","article-title":"LC-MF-4, a novel FGFR3 degrader for therapeutic intervention in FGFR3-altered cancers","volume":"68","author":"Zheng","year":"2025","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.tips.2025.09.004_bb0395","doi-asserted-by":"crossref","DOI":"10.1080\/19420862.2021.1981202","article-title":"Preclinical characterization of bemarituzumab, an anti-FGFR2b antibody for the treatment of cancer","volume":"13","author":"Xiang","year":"2021","journal-title":"MAbs"},{"key":"10.1016\/j.tips.2025.09.004_bb0400","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1007\/s10120-024-01466-w","article-title":"Bemarituzumab as first-line treatment for locally advanced or metastatic gastric\/gastroesophageal junction adenocarcinoma: final analysis of the randomized phase 2 FIGHT trial","volume":"27","author":"Wainberg","year":"2024","journal-title":"Gastric Cancer"},{"key":"10.1016\/j.tips.2025.09.004_bb0405","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1016\/S1470-2045(22)00603-9","article-title":"Bemarituzumab in patients with FGFR2b-selected gastric or gastro-oesophageal junction adenocarcinoma (FIGHT): a randomised, double-blind, placebo-controlled, phase 2 study","volume":"23","author":"Wainberg","year":"2022","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.tips.2025.09.004_bb0410","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.1158\/0008-5472.CAN-23-3195","article-title":"A tetravalent bispecific antibody selectively inhibits diverse FGFR3 oncogenic variants","volume":"84","author":"Yang","year":"2024","journal-title":"Cancer Res."},{"key":"10.1016\/j.tips.2025.09.004_bb0415","doi-asserted-by":"crossref","first-page":"7819","DOI":"10.1073\/pnas.1822055116","article-title":"Structures of ligand-occupied beta-Klotho complexes reveal a molecular mechanism underlying endocrine FGF specificity and activity","volume":"116","author":"Kuzina","year":"2019","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.tips.2025.09.004_bb0420","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1038\/nature25451","article-title":"alpha-Klotho is a non-enzymatic molecular scaffold for FGF23 hormone signalling","volume":"553","author":"Chen","year":"2018","journal-title":"Nature"},{"key":"10.1016\/j.tips.2025.09.004_bb0425","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1016\/j.str.2017.06.016","article-title":"Regulation of receptor binding specificity of FGF9 by an autoinhibitory homodimerization","volume":"25","author":"Liu","year":"2017","journal-title":"Structure"},{"key":"10.1016\/j.tips.2025.09.004_bb0430","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1038\/s41586-022-04654-9","article-title":"Design of protein-binding proteins from the target structure alone","volume":"605","author":"Cao","year":"2022","journal-title":"Nature"},{"key":"10.1016\/j.tips.2025.09.004_bb0435","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2022.111545","article-title":"Isoform-specific inhibition of FGFR signaling achieved by a de-novo-designed mini-protein","volume":"41","author":"Park","year":"2022","journal-title":"Cell Rep."},{"key":"10.1016\/j.tips.2025.09.004_bb0440","doi-asserted-by":"crossref","first-page":"3726","DOI":"10.1016\/j.cell.2024.05.025","article-title":"Modulation of FGF pathway signaling and vascular differentiation using designed oligomeric assemblies","volume":"187","author":"Edman","year":"2024","journal-title":"Cell"},{"key":"10.1016\/j.tips.2025.09.004_bb0445","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1038\/s42256-025-01095-7","article-title":"Electron-density-informed effective and reliable de novo molecular design and optimization with ED2Mol","volume":"7","author":"Li","year":"2025","journal-title":"Nat. Mach. Intell."},{"key":"10.1016\/j.tips.2025.09.004_bb0450","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.189307","article-title":"TYRA-300, an FGFR3-selective inhibitor, promotes bone growth in two FGFR3-driven models of chondrodysplasia","volume":"10","author":"Starrett","year":"2025","journal-title":"JCI Insight"},{"key":"10.1016\/j.tips.2025.09.004_bb0455","doi-asserted-by":"crossref","first-page":"3627","DOI":"10.1021\/acs.jcim.2c00633","article-title":"Identification of small-molecule inhibitors of fibroblast growth factor 23 signaling via in silico hot spot prediction and molecular docking to alpha-Klotho","volume":"62","author":"Liu","year":"2022","journal-title":"J. Chem. Inf. Model."},{"key":"10.1016\/j.tips.2025.09.004_bb0460","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1038\/s41589-019-0455-7","article-title":"Molecular basis for receptor tyrosine kinase A-loop tyrosine transphosphorylation","volume":"16","author":"Chen","year":"2020","journal-title":"Nat. Chem. Biol."}],"container-title":["Trends in Pharmacological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165614725002202?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165614725002202?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,9]],"date-time":"2025-11-09T07:40:56Z","timestamp":1762674056000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0165614725002202"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":92,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["S0165614725002202"],"URL":"https:\/\/doi.org\/10.1016\/j.tips.2025.09.004","relation":{},"ISSN":["0165-6147"],"issn-type":[{"value":"0165-6147","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Next-generation isoform-selective fibroblast growth factor receptor inhibitors","name":"articletitle","label":"Article Title"},{"value":"Trends in Pharmacological Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.tips.2025.09.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}